Electrospray Ionization-Ion Trap Mass Spectrometry Study of PQAAPro and PQProAA Mimetic Derivatives of the Antimalarial Primaquine  by Vale, Nuno et al.
Electrospray Ionization-Ion Trap Mass
Spectrometry Study of PQAAPro and
PQProAA Mimetic Derivatives of the
Antimalarial Primaquine
Nuno Vale,a Joana Matos,a Rui Moreira,b and Paula Gomesa
a CIQUP, Chemistry Department, Faculty of Sciences, University of Porto, Porto, Portugal
b iMed.UL, Institute for Medicines and Pharmaceutical Sciences, Faculty of Pharmacy, University of Lisbon,
Lisbon, Portugal
Electrospray ionization-ion trap mass spectrometry (ESI-MS) of imidazolidin-4-one peptido-
mimetic derivatives of the antimalarial drug primaquine (PQ) is reported. These compounds
contain the imidazolidin-4-one moiety either at the N- or the C-terminal of a dipeptide
backbone, thus respectively mimicking PQ-Amino Acid-Proline (PQAAPro) and PQProAA
derivatives of PQ. Both the peptidomimetics and precursors previously developed by us are
promising drug candidates, as they were found to be active against rodent Plasmodium berghei
malaria and Pneumocystis carinii pneumonia. Collision-induced dissociation (CID) and tandem-
mass spectra (MS) of the title compounds, and fragmentation pathways thereof, led to the
following findings: (1) CID patterns present some parallelism with the reactivity towards
hydrolysis previously found for the same or related compounds; (2) a positional shift of the
imidazolidin-4-one ring is reflected on both degree and pathways of fragmentation, which
makes tandem-MS a key tool for differentiation of imidazolidin-4-one isomers; (3) the major
MS/MS fragmentation of PQProAA mimetics involves release of a neutral diketopiperazine
(DKP), in parallel to the “diketopiperazine pathway” described in tandem-MS studies of
oligopeptides; (4) the relative abundance of a major fragment in tandem-MS spectra is
inversely correlated with the size of the N-terminal AA in PQProAA mimetics. Overall, this
work embodies an original and valuable contribution towards a deeper insight into the
molecular properties of novel antimalarials, which can be viewed as representative of both the
8-aminoquinoline and, especially, the imidazolidin-4-one structural classes. (J Am Soc Mass
Spectrom 2008, 19, 1476 –1490) © 2008 American Society for Mass SpectrometryOver the past decade, electrospray ionizationmass spectrometry (ESI-MS) has been used forthe most diverse analytical purposes. This tech-
nique has provided deeper insight into the structural
properties and stability of numerous compounds, from
natural products [1–3] to synthetic drugs [4–8], pep-
tides [9 –23], and heterocycles [24 –28], among many
others. Notwithstanding, little has been done on the
application of this technique to the study of relevant
antimalarials such as primaquine (PQ, 1) or related
structures. Analytical methods focused on PQ or its
analogues have been so far applied to pharmacokinetics
studies and metabolite scrutiny [29 –37] or isomer char-
acterization [38, 39]. Examples of mass spectrometry
techniques employed to the study/analysis of PQ and
related compounds include fast atom bombardment
mass spectral (FAB-MS) analysis of PQ oxidation prod-
ucts [32] and supercritical fluid chromatography-mass
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doi:10.1016/j.jasms.2008.06.019spectrometry (SFC-MS) used to elucidate differences in
the MS fragmentation patterns of PQ (free base), PQ
diphosphate and its positional isomer quinocide and to
achieve good resolution between these three com-
pounds in short analysis times [36]. Apart from very
few exceptions, such as the identification of the
8 - aminoquinoline (8-AQ) NPC 1161 and its metabolites
in biological samples [37], or studies on antimalarial
compounds reported by Nicolas et al. [5], Smyth et al.
and O’Donnell et al. [1, 2], ESI-MSn techniques have
seldom been employed to the characterization of anti-
malarial 8-AQ, and much less to PQ or its analogues.
Our research group has been working on the devel-
opment of PQ derivatives with antimalarial activity and
increased oral bioavailability, obtained by N-acylation
of the parent drug with amino acids and further mod-
ification of the N-acyl derivatives (2) by insertion of an
imidazolidin-4-one moiety (3) [40–45], which is com-
monly employed in the design of protease-resistant
peptidomimetics [46–52].
Structures like 3were found to be significantly active
as gametocytocides in rodent P. bergheimalaria [41] and
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a chloroquine-resistant strain of P. falciparum [44], the
causative agent of the deadliest form of human malaria.
They were also active against P. carinii, an opportunistic
fungus that is responsible for pneumocystic pneumonia
affecting immune-suppressed mammal hosts [44]. This
bioactivity pattern reflects the therapeutic profile of PQ
itself, but hydrolysis studies have shown imidazolidin-
4-ones 3 to be astonishingly stable, thus being active per
se [40–42]. To get a better understanding of structural
properties of compounds derived from 3, we have
recently engaged in an ESI-MS study of a family of 20
such compounds [45]. Experiments by CID in the nozzle-
skimmer region (NSR) and by tandem-MS have shown
imidazolidin-4-ones 3 to be remarkably stable, reflect-
ing our observations in aqueous media despite the
distinct degradation pathways [45]. We have now
stepped forward to the synthesis and study of two new
families of PQ imidazolidin-4-ones, 5 and 6, obtained
from PQ.
N-dipeptidyl derivatives (4) or by acylation of the
imidazolidin-4-one’s N-1 in 3, respectively (Scheme 1).
These compounds were designed as mimetics of, re-
spectively, PQAAPro and PQProAA peptide deriva-
tives of primaquine, resistant to oxidative deamination
[53, 54]. Full characterization of 5 and 6 passes by the
Scheme 1. Synthetic routes to Compounds 5 and
TEA, DCM, 0 °C to r.t.; (b) neat TFA, aq. 30%
TEA, DCM, 0 °C to r.t.; (d) neat TFA or TFA 5
TEA, MeOH, reflux; (f) propanone (R2  R3
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R1HOBt, TEA, DMF, 10 °C to r.t., inert atmosphereestablishment of MS fragmentation patterns that can be
used for reactivity predictions. To that purpose, we
have carried out a thorough study of 5 and 6 by CID
and tandem-MS analysis, whose results are herein
reported and discussed.
Experimental
Chemistry
Synthesis of compounds PQAAPro mimetics (5). The syn-
thetic route to Structures 5 is depicted in Scheme 1a–e.
Briefly, PQ was coupled to an N-tert-butyloxycarbonyl-
protected L-amino acid (BocAA1OH) through carbodi-
imide (di-isopropyl-, DIC, or dicyclohexyl-carbodiimide,
DCCI)/1-hydroxybenzotriazole (HOBt)-mediated con-
densations in dichloromethane (DCM) and in the pres-
ence of triethylamine (TEA). The tert-butyloxycarbonyl
(Boc) group was then removed by acidolytic cleavage
with trifluoroacetic acid (TFA), and the resulting triflu-
oroacetate was converted into the free base by neutral-
ization with aqueous (aq) Na2CO3. A second amino acid
residue (BocAA4OH) was coupled by similar proce-
dures and, after Boc removal with TFA, followed by
neutralization with aq Na2CO3 to release intermediates
4; these were reacted with ketones (propanone, cyclo-
hexanone, 4-methylcyclohexanone, and cycloheptanone) to
yield the target imidazolidin-4-one Structures 5. These
were successfully characterized by either ESI-MS or
matrix-assisted laser desorption-time-of-flight (MALDI-
TOF) MS as well as by proton (1H-) and carbon (13C-)
nuclear magnetic resonance (NMR), as reported else-
where [53].
, 43, 53, 54]: (a) BocAA1OH, DCCI or DIC, HOBt,
O3, r.t.; (c) BocAA
4OH, DCCI or DIC, HOBt,
DCM, aq. 30% Na2CO3, r.t.; (e) R
2(C  O)R3,
e), TEA, MeOH, reflux; (g) BocAA4OH, DIC,6 [40
Na2C
0% in
 M; (h) TFA 30% in DCM, aq. 30%Na2CO3.
1478 VALE ET AL. J Am Soc Mass Spectrom 2008, 19, 1476–1490Synthesis of compounds PQProAA mimetics (6). Struc-
tures 6 were obtained by coupling an N-Boc-protected
L-amino acid (BocAA4OH) to imidazolidin-4-ones 3,
whose synthesis has been described elsewhere [40, 43],
and is depicted on Scheme 1a, b, and f. Coupling of
BocAA4OH to Compounds 3 was carried out also by
means of a carbodiimide (DIC) as coupling agent and
HOBt as the auxiliary nucleophile (Scheme 1g) in N,N-
dimethylformamide (DMF). After Boc removal with a
solution of TFA in DCM followed by neutralization
with aq Na2CO3, Compounds 6 were well obtained and
characterized by MALDI-TOF or ESI-MS, 1H-NMR and
13C-NMR, as recently reported [54].
Synthesis of PQProAla (4.1). As imidazolidizin-4-ones
are often used as proline surrogates [55–57], we have
also prepared the N-alanylprolyl derivative of PQ
(PQProAla, 4.1) through steps Scheme 1a–d, using
BocProOH and BocAlaOH as, respectively, BocAA1OH
and BocAA4OH (spectroscopic data for compound 4.1
is provided in the Supporting Information file). This
targeted the inclusion of 4.1 in the MS fragmentation
studies of the title compounds, for comparison
purposes.
Table 1. PQ (1) and derivatives (4, 5, and 6) covered by the pre
their corresponding full-MS spectra
Compound R1 R2 R3 R
5.1 H H
5.2 H Me
5.3 Me Me Me H
5.4 Me Me
5.5 Me (CH2)2S
5.6 H Bzl
5.7 H Bzl
5.8 H CH3
5.9 Me H
5.10 Me (CH2)5 Me
5.11 Me (CH2)2S
5.12 iBu H
5.13 Bzl H
5.14 H (CH2)2CH(Me)(CH2)2 Bzl
5.15 H (CH2)6 Bzl
6.1 H H
6.2 H Me
6.3 H iPr
6.4 H iBu
6.5 H Me Me CH(Me
6.6 H (CH2)2S
6.7 H Bzl
6.8 Me H
6.9 iBu H
1 — — — —
4.1 -(CH2)3- — — MeESI-MSn Analysis
ESI-MSn studies on Compounds 1, 4.1, 5.1–5.15, and
6.1–6.9 (Table 1) were achieved using a Finnigan
Surveyor LCQ DECA XP MAX quadrupole ion trap
mass spectrometer, utilizing electrospray ionization.
Methanolic solutions of the compounds containing
0.1% acetic acid were infused into the ESI probe at a
rate of 3 L/min. All other details of the experimen-
tal setup in the MS studies were as recently described
[45], with the exception that the Vs CID parameter
varied between 10 and 100 V in fragmentation studies
on the NSR. The relevance of the experimental proce-
dures adopted in our MS studies have been recently
explained in our previous work concerning compounds
derived from 3 [45].
All ESI-MSn spectra obtained are supplied in the
Supporting Information file, which can be found in the
electronic version of this article.
Results and Discussion
Experiments in the Nozzle-Skimmer Region
Compounds from both families, 5 and 6, were analyzed
in the NSR at CID potentials of 10, 25, 50, 75, and 100 V
study, and average m/z values for the main species detected in
MW/g mol1 m/z [M  H] m/z [M  Na]
413.24 414.80 437.33
427.26 428.93 450.80
427.26 428.87 450.87
441.27 442.80 465.27
501.28 502.20 525.07
503.29 504.87 526.87
543.32 544.87 566.73
467.29 468.93 490.93
467.29 468.73 491.00
481.31 482.93 504.80
541.31 542.87 564.80
509.34 510.80 533.27
543.32 544.93 567.07
557.34 558.80 580.67
557.34 558.93 580.67
413.24 414.87 436.87
427.26 428.98 451.07
455.29 456.93 478.73
469.31 470.47 492.67
e 469.31 470.93 492.73
487.26 489.18 510.87
503.29 504.88 526.87
427.26 428.67 450.53
469.31 471.13 492.13
259.17 260.72 —sent
4
Me
Me
)CH2M
Me427.26 428.93 450.80
e das
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types of structures were overall stable to fragmentation
under these conditions and presented similar dissocia-
tion patterns, related to those previously observed for
the precursor Structures 3 [45]. Generally, spectra from
PQAAPro mimetics (5) contained fewer product ions
than those from PQProAA mimetics (6).
Predominant species on the CID spectra of imidazolidin-
4-ones 5 were basically the quasi-molecular ions of the
original compound, [MH], its sodium adduct, [M
Na], its dimer [M2  H]
, or the sodium adduct of the
latter, [M2  Na]
. Nonetheless, fragmentation patterns
could be clearly drawn, which consistently included peaks
at m/z 175, 243, 132, and ([M  H])-176. These were
respectively assigned to the quasimolecular ions ([M 
H]) of 6-methoxy-8-aminoquinoline (MAQ, 7 on Scheme
2), “desamino”-PQ (8 on Scheme 2, 6-methoxy-N-(pent-
4-en-2-yl)quinolin-8-amine), 7,8-dihydroquinoline (DHQ, 9
on Scheme 2) and the fragment of 5 obtained after loss
of MAQ and dehydrogenation (10a in Scheme 2). As-
signment of the peak at m/z 132 to DHQ was based on
our previous work [45] as well as on the reported
identification of this species as the major product of MS
2 fragmentation of nicotine [1]. These and other relevant
product ions are illustrated by the CID spectrum of 5.6,
Scheme 2. Main fragmentations and associated
(above the dashed line) and 6 (below the dashed
text). Common fragments are displayed over thin Figure 1.By comparing results for different R1/R4 pairs of
amino acids, structure-reactivity correlations cannot be
clearly obtained from CID experiments. The presence of
one Gly at either position (R1 or R4  H), as in
Compounds 5.2, 5.3, and 5.6, yields higher percentages
of the above mentioned 8-AQ fragments (7, 8, and 9)
than Compounds 5.4 and 5.5 where R1 and R4  H
(relevant spectra in Supporting Information). This
could be interpreted as due to a higher sensitivity
associated to Gly-bearing compounds, but 5.1 that con-
tains two Gly residues (R1  R2  H) presents a lower
fragmentation degree while displaying strong associa-
tion with sodium cations. Besides these specific exam-
ples of Gly-containing structures, all compounds of the
subset 5.1–5.6 display virtually the same fragmentation
pattern, irrespective of the nature or relative position of
amino acids at both R1 and R4. The same occurred with
their analogues derived from cycloketones (5.7 to 5.15),
though spectra from this second subset tend to display
fewer product ions than those from the first one (cf.
relevant spectra in Supporting Information).
The particular case of 5.11, which bears a methionine
residue, is also noteworthy, as oxidation of its thioether
sulphur to a sulfone was observed. This is a current in
ments, observed for compounds derived from 5
in the course of ESI-MS analyses in the NSR (see
hed line.frag
line)vivo phenomenon for peptides and proteins, whose
nds 5
1480 VALE ET AL. J Am Soc Mass Spectrom 2008, 19, 1476–1490Met residues easily undergo oxidation to methionine
sulfone [58–61].
Other important peaks were observed in CID spectra
at low collision energies, associated to imidazolidin-4-
one ring breaking. For instance, the CID spectra of 5.7 at
10 and 25 V (Supporting Information) display peaks at
m/z 398 and at 371 that were, respectively, attributed to
loss of the imidazolidin-4-one’s amino acid building
block (Phe) yielding 11 (Scheme 2), and to loss of R2, R3,
and R4 to give 12 (Scheme 2). At higher collision
energies, these species tended to disappear, due to their
dissociation into smaller product ions such as 7–9,
further contributing to the prominence of these ions
in spectra acquired at CID 50 V. Nevertheless, in
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Figure 1. Fragmentation spectra for Compouour viewpoint the key fragmentation in Structures 5was the loss of 345 Da, as it results from imidazolidin-
4-one ring-opening with concomitant release of N-
(formamidomethylcarbonyl)primaquine (13 in Scheme 2).
In many cases, this was the most important fragmen-
tation at CID 75 V (spectrum of 5.6 on the top of
Figure 1), and was found to be a key feature for the
structural distinction between isomeric Structures 5
and 6, as only the first ones display imidazolidin-4-
one ring opening as a result of collision-induced
dissociation (compare spectra of 5.6 and of its isomer
6.7 on Figure 1).
In fact, by comparing spectra obtained for Com-
pound 5.6 and its isomer 6.7, two features are immedi-
ately eye-catching: (1) the spectrum of 6.7 present fewer
0 1200 1400 1600 1800 200
/z
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1068.87
1249.60
1539.67 1683.87 1870.20
1200 1400 1600 1800 2000
3
083.60 1510.801355.20 1694.53 1876.53
[M2+Na]
+
[M2+Na]
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m
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.87
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029.3
1product ions than that of 5.6, and (2) there is no
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The distinct behavior of 6.7, compared with that of its
isomer 5.6, was consistently observed for all com-
pounds derived from 6 whose imidazolidin-4-one rings
thus seem to be more stable towards fragmentation in
the NSR region than those on their 5 analogues. In other
words, shift of the imidazolidin-4-one ring from the
N-terminus of the dipeptide backbone (i.e., as in 5) to
the C-terminus (i.e., as in 6) leads to a significant
decrease in the reactivity of the five-membered ring,
observable at all voltages used (relevant spectra in
Supporting Information). Thus, in general, main in-
source fragmentations of compounds derived from 6
are practically limited to loss of MAQ (7) and of
“desamino”-PQ (8).
To sum up, the in-source fragmentation behavior is
practically superimposable for all compounds belong-
ing to the same family, i.e., to 5 or to 6, as the same main
product ions are consistently observed. Despite major
CID pathways of 5 being similar to those previously
described for 3, these compounds were apparently
more stable and did not suffer imidazolidin-4-one ring
disruption under similar conditions [45]. This indicates
that insertion of one AA residue between the parent
drug and the imidazolidin-4-one scaffold might render
the latter slightly less stable towards in-source fragmen-
tations. On the other hand, Structures 6, like their
precursors 3, also bear an imidazolidin-4-one ring stable
towards collision-induced dissociation, demonstrating
that N-acylation of the imidazolidin-4-one’s N-1 atom
with an amino acid does not decrease the ring’s stability
in the NSR. Interestingly, this correlates with our pre-
vious observations regarding the stability of these three
families of compounds in aqueous solution at physio-
logical pH and T [41, 42, 53, 54].
ESI-MS2Analysis at Varying NCE Values
The experimental setup chosen to carry out ESI-MS2
analyses on compound families 5 and 6 was identical to
that recently described by us for similar studies on the
related compounds derived from 3 [45]. The parent drug
(PQ, 1) and its N-dipeptidyl derivative PQProAla (4.1)
were also included in the study, for comparison. As
shown by data in (Supplementary Information Table S1),
at normalized collision energy (NCE) values of 10 and
20%, the base-peak in MS2 spectra of all compounds
assayed was still the quasi-molecular ion [M  H].
Fragmentations were only significant at NCE  30%,
and allowed finding relevant differences both between
the two series of peptidomimetics (5 and 6) as well as
between these, the parent drug (1) and its dipeptide
derivative 4.1. As discussed below, 5 and 6 were found
to be substantially more stable than both their parent
drug (1) and their dipeptide analogue (4.1). Moreover,
the distinct behavior of 5 and 6 in tandem-MS experi-
ments may serve as a basis for differentiation of isomers
in structures bearing imidazolidin-4-one cores.MS2 Fragmentation Pattern of PQAAPro
Mimetics (5) at NCE  30%
At NCE values of 30% and 40%, MS2 spectra of all
PQAAPro mimetics (5) had their base-peak atm/z ([M
H])-174, corresponding to fragment 10a (Schemes 2
and 3) formed upon loss of MAQ (7). This behavior
reproduces what has been previously observed for
imidazolidin-4-one structures like 3, recently reported
[45]. Other minor, yet relevant, fragmentations consis-
tently appeared in the MS2 spectra of compounds based
on the 5 scaffold at NCE 30%. Namely, MS2 spectra of
such compounds derived from propanone (R2  R3 
Me in 5.1 to 5.6) all exhibit a peak whose m/z is
compatible with the loss of 75 Da, independently of the
amino acid side chains (R1 and R4) present. Similar
observations for compounds derived from cyclohex-
anone (5.7–5.13) were made, but in this case relevant
mass losses were of 18, 115 and 147 Da. The fact that
mass loss values were independent of R1 and R4 shows
that fragmentations must occur at either the 8-AQ ring
or the imidazolidin-4-one’s C-2, with small fragments
being detached and the detected ion still bearing the
amino acid side chains intact. As the observed values of
m/z were too small to be easily explained by fragmen-
tations exclusively at the 8-AQ level, degradation of the
imidazolidin-4-one’s ring is proposed (Scheme 3) that
provides explanation for both them/z values detected and
their dependency on the nature of the C-2 substituent
groups (R2 and R3). Thus, loss of 75 Da from Com-
pounds 5.1–5.6 can be explained by concomitant release
of methane from the 8-AQ 6-methoxy substituent and
isopropylamine from the imidazolidin-4-one ring, with
formation of species 14 (Scheme 3). A similar fragmen-
tation occurs for Compounds 5.7–5.13, except that cy-
clohexylamine is released instead of isopropylamine,
which agrees with the loss of 115 instead of 75 Da.
Further release of two water molecules from 5.7–5.13
leading to 15 would explain the loss of 147 Da. Loss
of one of these water molecules before release of
methane  alkylamine justifies the occasional observa-
tion of peaks corresponding to loss of 18 Da from the
parent Structure 5. In the particular case of 5.14 and
5.15, mass losses of 18 (m/z 540) and 147 Da (m/z 411)
were observed, consistent with similar dissociation
steps, i.e., water elimination followed by concomitant
release of methane and 4-methylcyclohexylamine (5.14)
or cycloheptylamine (5.15) to produce 16 (Scheme 3).
Globally, the MS2 fragmentation behavior of Structures
5 at NCE  30% obeys to a general common pattern,
with detachment of MAQ as the main fragmentation
pathway. The elimination of MAQ (7) agrees with both
our previous work [45] and the reported LC/ESI-MS
characterization of PQ (1) and its major contaminant
quinocide, carried out by Brondz et al. [36]. Other
relevant fragmentations were essentially based on con-
comitant and/or sequential loss of small molecules
such as methane, water and alkylamines, involving
opening of the imidazolidin-4-one ring while keeping
1482 VALE ET AL. J Am Soc Mass Spectrom 2008, 19, 1476–1490the quinoline ring intact. As illustrated on the insert in
Scheme 3, we believe the ring opening to be a charge-
driven process, as a result of the initial protonation of
Structures 5 at the imidazolidin-4-one’s N-1 atom.
These findings are in overall agreement with previ-
ous findings by Smyth and coworkers, in the course of
ESI-MSn studies of selected drugs [6, 26–28].
MS2 Fragmentation Pattern of PQProAA
Mimetics (6) at NCE  30%
MS2 fragmentations of PQProAA mimetics (6), though
sharing release of MAQ (7) and/or of “desamino”-PQ
(8) with their isomers 5, presented unique characteris-
tics. Explicitly, MS2 spectra obtained at NCE  30% for
Scheme 3. Proposed fragmentations of Compo
MS2 spectra at NCE 30%. The insert depic
quasi-molecular ion 5  H that suffers the subs
4-one ring (see text).all Structures 6, except that where R1  R4  H (6.1),presented the base-peak at m/z 300, an observation
exclusively made for these compounds (relevant spec-
tra in Supporting Information). In some cases, the
difference in intensity between this and the peak due to
10b formed by loss of MAQ (Schemes 2 and 4) was
minimal, whereas at NCE  40% the base-peak was
usually that at m/z 243, assigned to 8 (Figure 2). Addi-
tionally, some minor peaks were consistently observed
for all Compounds 6.1–6.9, namely, a peak at m/z 215
and another due to loss of 75 Da from the original
compounds derived from 6.
Scheme 4 illustrates the pathways proposed to ex-
plain the observations exclusive for MS2 spectra of
PQProAA mimetics 6. First, the transient formation of the
iminium intermediate 17 can justify the formation of ion
5, according to peaks consistently observed in
assumed protonation site of 5 to yield the
nt charge-driven disruption of the imidazolidin-unds
ts the
eque18 whose m/z is 300. This species could be produced
g to p
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tion of 19, with concomitant release of a neutral
2,5-diketopiperazine (DKP, 19), a mechanism that is
parallel to what has been described for tandem-MS
fragmentations of oligopeptides [9–17]. In the so-called
Scheme 4. Fragmentation routes for 6, accordinFigure 2. MS2 spectra of 6.2 at NCE 30% (left) and 4“diketopiperazine pathway”, first reported by Cordero
et al. [9] and then thoroughly explored by Paisz and
Suhai [10–13], the oligopeptide is described to undergo
O-protonation of its N-terminal amide carbonyl, after
which proton transfer to the amide nitrogen and cis-
eaks steadily observed in ESI-MS2 at NCE 30%.0% (right) (expanded between m/z 100 and 500).
1484 VALE ET AL. J Am Soc Mass Spectrom 2008, 19, 1476–1490trans isomerization of the amide bond occur before
intramolecular attack of the N-terminal primary amine
to the N-terminal amide carbonyl. As cis-trans isomer-
ization step is a requirement of the “diketopiperazine
pathway”, this is expectedly more favored in oligopep-
tides where the N-terminal AA is directly linked to Gly,
Sar, or, especially, Pro as the second AA in the sequence
[10–13, 62]. Indeed, the gas-phase structure of a Pro-
containing b2 ion was recently confirmed to be a DKP
[14] and it is reasonable to expect that a similar frag-
mentation pathway can occur on peptidomimetic struc-
tures as 6 that bear Pro-like building blocks. In the
particular case of these compounds, they must be first
protonated at the imidazolidin-4-one’s N-1 atom, which
leads to ring opening by disruption of the C-2–N-2
bond, yielding the iminium ion 17. This ion can be
regarded as a C-terminally modified tripeptide mimetic
that, by virtue of its origin from the imidazolidin-4-one
6, is most probably already adopting the correct confor-
mation for the cyclization-elimination reaction to readily
take place, producing both the neutral DKP and ion 18.
Additional support to the above hypothesis comes
from the fact that 18 can be further degraded by loss of
small molecules such as formaldehyde and isopro-
pylamine, leading to formation of N-(2-pentyl)quinolin-
8-amine (20) at m/z 215 (Scheme 4). Moreover, both
the iminium intermediate 17 and the original Com-
pound 6 can lose formaldehyde and propane to give
species 21 that has less 75 Da than the original
Compound 6. Formation of 21 explains the consistent
observation of peaks due to a constant mass loss of 75
Da from Structures 6, independent of the nature of
both R1 and R4. Species 21 could eventually also
undergo a cyclization-elimination reaction to release
neutral 2,5-dihydroxypyrazines 22, further contribut-
ing to formation of 20 (m/z 215) through additional
loss of ammonia (Scheme 4).
MS2 fragmentation of 6 involving formation of 18 is
further supported by the regular observation of minor
peaks at m/z 286 (for 6.1, 6.2, 6.7, 6.8) and at m/z 256 (6.4,
6.5, 6.6, 6.9), assigned to loss of methane and isopro-
pane, respectively, from 18. Finally, the fragmentation
pathway proposed in Scheme 4 is reinforced by MS3
fragmentations focused on the ion isolated atm/z 300, as
discussed in an earlier section.
Overall, routes proposed in Scheme 4 do not only
explain key peaks in MS2 spectra of peptidomimetics 6
at NCE 30%, but also justify why many of those peaks
are exclusive of these compounds, not being detected
on similar experiments with either their isomers 5 or
their precursors 3. It could be argued that formation of
21 is parallel to some dissociation steps proposed for type
5 structures (Scheme 3), i.e., imidazolidin-4-one ring open-
ing with expulsion of C-2 and its substituent groups.
However, in PQProAA mimetics 6, the imidazolidin-4-
one’s N-1 has to remain attached to the major fragment
detected, otherwise mass losses higher than 75 Da
had to be detected. The different behavior of 5 and 6
regarding ring opening suggests that BDE(C-2–N-1)in 6  BDE(C-2– N-1) in 5, which is consistent with
the fact that N-1 is part of a tertiary amide in the
former, whereas it is a secondary amine in the latter.
Fragmentation Patterns of the Parent Drug, 1, and
of the Imidazolidinone Mimetic 4.1
As mentioned before, the behavior of both 4.1
(PQProAla), the dipeptide derivative mimicked by 6.2
and 1, the parent drug was also studied under identical
conditions (Table S1 and spectra in Supplementary
Information). MS2 fragmentations of PQ (1) were lim-
ited to loss of ammonia to yield 8 and its further degradation
into MAQ (7). Relevantly, MS2degradations of both 1 and
4.1 were already detected at NCE 20% and at NCE 30%,
relative abundances of MAQ (7) were much lower for
imidazolidin-4-ones 5 and 6 than for 1 and 4.1, which
had completely disappeared at that NCE value (Table
S1). Fragmentations of 4.1 included dehydration (m/z
410), release of PQ (m/z 260), and its further fragmen-
tation into 8 (m/z 243) and into 7 (m/z 175). Interest-
ingly, release of PQ from Compounds 5 or 6 was not
significant under identical conditions, which pro-
vides grounds to conclude that use of pseudo-proline
dipeptide carriers such as in 5 or 6 renders the
PQ-carrier bond much stronger.
The effect of replacing Pro by its imidazolidin-4-one
surrogate in 6 on the detachment of the AA condensed
to the pentagonal ring was also analyzed. This was a
minor MS2 fragmentation for both 4.1 and 6 that led to
release of PQPro and Structures 3, respectively. A
ranking of the relative intensities of peaks correspond-
ing to the relevant fragments could be established
(Figure 3), allowing to observe that Ala is more
promptly released from 4.1 than from its analogue 6.2,
and also that the ease of release of the amino acid
directly linked to the imidazolidin-4-one N-1 depends
on the nature of that same amino acid, as detachment of
those bearing larger, -branched, R4 side chains (6.3,
6.5) occurs at higher extension. Interestingly, Com-
pounds 6 that are more prone to release the amino acid
coupled to the imidazolidin-4-one’s N-1 are those with
a lower ability to release MAQ (Table S1, Figure 3),
which explains why 10b is the most abundant MS2
product ion only for 6.1 (R4  H).
Figure 3. Relative abundance of the species due to loss of the
amino acid linked to the pentagonal ring in 4.1 and 6.1–6.9.
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10b and the Substituent Group R4
From the findings described in the above subsection, the
question immediately arose whether the relative abundance
of fragment 10b, formed upon loss of MAQ from Com-
pounds 6 (Schemes 2 and 4), couldbe correlatedwith the size
of the amino acid’s side chain R4. Therefore, we selected the
subset of Compounds 6.2, 6.3, 6.4, 6.5, 6.7 that shared glycine
as the first amino acid residue (R1  H) and contained
different amino acids attached to the imidazolidin-4-one’s
N-1, so that the respective side chains (R4) were associated
to different values of the Charton’s steric parameter,  [63].
The log of the relative abundances of species 10b gener-
ated from that subset of compounds was then represented
against the value of  associated to each R4 (Supplemen-
tary Information Table S2) resulting in the perfect linear
correlation shown on Figure 4. As far as we know, this is
the first time that tandem-MS fragmentation patterns have
been correlated with purely steric factors.
The negative slope obtained indicates that steric
crowding imposed by the amino acid’s side-chain R4
partially inhibits or delays the formation of 10b, thus
rendering the parent Compounds 6more stable under the
fragmentative conditions employed. In contrast, no corre-
lation with the electronic Taft * parameter [63] was
found. Possibly Compounds 6 adopt a folded conforma-
tion in the gas phase, with voluminous R4 groups exerting
some kind of shielding effect over the bond that is broken
to yield 10b. Folded conformations in the gas phase have
been previously obtained in geometry optimization stud-
ies focused on the precursor Compounds 3 [43], which
gives support to the above hypothesis.
ESI-MSn Analysis at NCE  30%
As described in the previous section, fragmentations occur
on peptidomimetics 5 and 6 only at 30% and higher NCE
values. Thus, to carry out a full study of the fragmen-
tation mechanisms of those PQ-derived imidazolidin-
4-ones, we have fixed the NCE at 30% and performed
an extended MSn analysis, following the experimental
Figure 4. Plot of log (relative abundance of 10b) versus the
Charton’s steric parameter, , associated to the amino acid’s
side-chain R4.setup given in an earlier section. MS2 analysis at
NCE  30% has been covered in the previous section
and will be no further discussed, except in what
concerns eventual inputs from MS3 and/or MS4 data
that may help to shed some additional light on the
MS2 fragmentation pathways above proposed.
Selection of fragments due to loss of MAQ for further
MSn studies of the title compounds led to MS3 and MS4
spectra that were globally similar for both families of
the peptidomimetic derivatives of PQ. As discussed
below, these spectra were consistent with fragmenta-
tions involving release of small molecules, including
amines and carbon monoxide. Further support to for-
mation of 18 from 6, as proposed in Scheme 4, was
provided by additional fragmentations of the ion iso-
lated at m/z 300.
ESI-MSn Study of PQAAPro Mimetics (5)
Ion 10a (Scheme 2) was selected for MSn fragmentation
studies on PQAAPro mimetics (5). Loss of 85 Da was the
main, and often the only, event registered on MS3 spectra
of these compounds, so that the MS3-generated fragment
with m/z ([10a  H])-85 was selected for further MS4
fragmentations. In these, loss of 28 Da was the most
relevant event consistently observed (Supplementary In-
formation Table S3). Scheme 5a illustrates the pathway
proposed according to the above findings, showing that
loss of 85 Da agrees with release of pent-4-en-1-amine,
yielding species 23a from which detachment of carbon
monoxide explains a further loss of 28 Da to produce the
main species, 24a, observed in MS4 spectra. Data obtained
does not allow ruling out the possibility that ethylene
(C2H4) instead of CO is detached from 23a, but the latter
molecule is more likely to have been released from the 23a
scaffold.
MS3 spectra of most compounds derived from cyclo-
hexanone (5.7–5.13) also showed fragmentation of 10a
to 23a as the main event, but often accompanied by
further fragmentation to 24a plus additional loss of 45
Da from the latter. At first, this could be ascribed to
release of propane due to concomitant disruption of the
imidazolidin-4-one and the cyclohexane rings, but such
would correspond to loss of only 44 Da. Therefore, loss
of 45 Da was probably due to release of carbon monox-
ide and ammonia, though it is difficult to explain why
this only happened for the cyclohexanone-derived
structures. Despite the higher number of relevant frag-
ments observed in MS3 spectra of 5.7–5.13 compared
with those of 5.1–5.6, relative abundances of unfrag-
mented 10a remaining after MS3 and MS4 experiments
were generally higher for cyclohexanone derivatives.
Particularly in the case of 5.14, an additional fragment
at m/z 242 was observed in the MS3 spectrum, repre-
senting loss of 57 Da from the corresponding species
23a. This was assigned to release of isobutane with
concomitant opening of both the 4-methyl-cyclohexane
and imidazolidin-4-one rings. Compound 5.15 also dis-
played the same general pattern, i.e., the main MS3
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whose further fragmentation in the MS4 experiment led
to the usual loss of 28 Da. The second most relevant
MS3-generated fragment of 5.15 was formed through
loss of 147 Da, assigned to opening of the imidazolidin-
4-one ring to release phenylalanine.
ESI-MSn Study of PQProAA Mimetics (6)
In what concerns the parallel study focused on
PQProAA mimetics 6 or, in better words, on their
MS2-derived fragments 10b (Scheme 2), loss of 85 Da
Scheme 5. Main ESI-MSn (n  3, 4) disinteg
corresponding MS2-generated fragments 10a (a)
are indicated by full arrows, whereas dashed
compound or subset of compounds (see text).in the course of MS3 experiments and loss of 28 Daby further (MS4 fragmentation of the main MS3-
generated species were also the most frequent situa-
tion, coherent with the degradation pathway pro-
posed in Scheme 5b. However, exceptions were
found for Compounds 6.4, 6.5, 6.6, and 6.8. In the first
two cases, the only difference was that no species
were detected in their MS4 spectra, which was attrib-
uted to the fact that the fragments eventually pro-
duced should have m/z  50, as this is the lower limit
of detection of the ESI-IT MS spectrometer used. In
what concerns 6.6, the main MS3-generated fragment
arose from loss of 58 Da, and its subsequent MS4
ns of Compounds 5 and 6 starting from the
0b (b), respectively. Major fragmentative events
s depict fragmentations particular to a givenratio
and 1
arrowfragmentation caused further loss of 85 Da. The same
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order, as the main species registered on the MS3
spectrum arose from loss of 85 Da and the ensuing
MS4 fragmentation led to loss of 58 Da. These obser-
Figure 5. MS3, MS4, and MS5 (top to bottom) f
spectra of 6 (illustrated for 6.2).vations were interpreted as sequential release of
butane and N-isopropyl-N-vinylamine, and vice
versa, as depicted on Scheme 5b steps B1 and B2. The
58-Da loss could be also due to acetone rather than
entations of the ion detected at m/z 300 in MS2ragm
1488 VALE ET AL. J Am Soc Mass Spectrom 2008, 19, 1476–1490butane release, but there is not enough experimental
evidence to provide a definitive answer.
Still in connection with the fragmentation studies of
Compounds 6, additional ESI-MSn experiments were
conducted to shed additional light on the structural
identification of the fragment detected at m/z 300 in the
MS2 spectra of all Compounds 6. The structure of such
fragment was proposed to be 18 (Scheme 4) and its
further fragmentation in the course of ESI-MSn experi-
ments at NCE 30% provided additional support to this
hypothesis, as it consistently led to formation of 8
together with another fragment at m/z 126 that agrees
with Structure 25 (Figure 5). Further fragmentations led
to decomposition of the aliphatic chain of 8 (Figure 5).
ESI-MSn Study of the Parent Drug, 1, and the
Imidazolidinone Mimetic Compound 4.1
In what concerns PQ (1), further disintegration of the
MS2-generated species 8 (m/z 243) was virtually impossi-
ble, as 8 was still the only species detectable in the MS3
andMS4 spectra of PQ, with the exception of a very minor
peak at m/z 175 (MAQ, 7) in the MS3 spectrum. The same
occurred for the proline-based analogue 4.1 which,
through detachment of the ProAla peptide as a result of
MS2 fragmentations, released PQ whose further disinte-
gration inMS3 andMS4 experiments expectedly led to 8 as
the major fragment and to 7 as the minor one.
Conclusions
Two families of peptidomimetic derivatives of PQ,
bearing the imidazolidin-4-one scaffold as a surrogate
of proline, were prepared and characterized by ESI-
MSn. The fragmentation behaviors of such compounds
were markedly different from those of both their parent
drug and a dipeptide derivative of the latter, with
peptidomimetics being significantly more stable to-
wards ESI-induced dissociation. Moreover, despite
sharing some of the major fragmentation routes, the
two families displayed relevant differences. Thus, when
comparing PQAAPro mimetics (5) with their isomers
from the PQProAA series (6), imidazolidin-4-one ring
seems more resistant to in-source fragmentation in the
latter than in the former. Strikingly, this behavior re-
flects recent observations regarding compound reactiv-
ity towards hydrolysis [53, 54]. This parallelism be-
tween compound reactivity to hydrolysis and stability
towards MS fragmentations had already been spotted
in the ESI-MSn studies of Compounds 3 [45]. Use of
ESI-MS studies as part of investigations on the hydro-
lysis mechanisms of biodegradable polyesters have
been conducted by others [24], showing that ESI-MS can
have a role for prediction of compound reactivity
towards hydrolysis. Though there is no clear-cut phys-
ical explanation for this, as mechanisms in water and in
the gas-phase are not comparable, the parallelism is
notable and should be object of future reflections.Tandem-MS analyses allowed establishing a frag-
mentation pathway exclusive for PQProAA mimetics 6,
similar to the “diketopiperazine pathway” described
for protonated oligopeptides. This was a key feature to
distinguish between both series of peptidomimetics, thus
providing a tool for differentiation of imidazolidin-4-one
positional isomers. To the best of our knowledge, nothing
of this kind was ever reported for imidazolidin-4-one
structures. Moreover, an unprecedented structure/ESI-
reactivity relationship could be drawn for the same
series of compounds, as the extension at which a major
MS2-fragmentation (loss of MAQ) occurs was seen to be
linearly dependent on the size of the AA attached to the
imidazolidin-4-one’s N-1.
Overall, this study contributes to establish structures
like 5 and, especially, 6, as remarkably stable peptido-
mimetic derivatives of PQ, with reported advantages
over their precursors 3 [54]. Some of the derivatives 6
have recently been found to display transmission-
blocking activities similar to those of the parent drug
PQ and of their precursors 3 [54]. Finally, this work is a
valuable contribution towards a deeper insight into the
properties of novel structures representing both the
8-AQ and the imidazolidin-4-one classes.
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